Supernus Pharmaceuticals (NASDAQ:SUPN) PT Lowered to $42.00
Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) had its target price trimmed by Piper Sandler from $43.00 to $42.00 in a report published on Wednesday, Benzinga reports. The firm currently has an overweight rating on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Supernus Pharmaceuticals from a hold rating to a buy rating in […]
More Stories
Amazon.com (NASDAQ:AMZN) Price Target Increased to $240.00 by Analysts at Morgan Stanley
Amazon.com (NASDAQ:AMZN) had its price objective upped by Morgan Stanley from $220.00 to $240.00 in a report issued on Tuesday,...
Pason Systems Inc. (TSE:PSI) Given Consensus Recommendation of “Moderate Buy” by Analysts
Pason Systems Inc. (TSE:PSI – Get Free Report) has been given an average recommendation of “Moderate Buy” by the five...
Zions Bancorporation, National Association (NASDAQ:ZION) PT Raised to $42.00 at Morgan Stanley
Zions Bancorporation, National Association (NASDAQ:ZION – Free Report) had its target price boosted by Morgan Stanley from $39.00 to $42.00...
Deutsche Bank Aktiengesellschaft Cuts Hershey (NYSE:HSY) Price Target to $192.00
Hershey (NYSE:HSY – Free Report) had its price objective reduced by Deutsche Bank Aktiengesellschaft from $197.00 to $192.00 in a...
Adtalem Global Education (NYSE:ATGE) Price Target Raised to $90.00
Adtalem Global Education (NYSE:ATGE – Free Report) had its target price upped by Barrington Research from $70.00 to $90.00 in...
JPMorgan Chase & Co. Trims Brunswick (NYSE:BC) Target Price to $75.00
Brunswick (NYSE:BC – Free Report) had its target price reduced by JPMorgan Chase & Co. from $78.00 to $75.00 in...